First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Drugs.com,
CHICAGO, March 1, 2023. Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating…
CHICAGO, March 1, 2023. Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating…
Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe CHICAGO, March 1…
Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe CHICAGO, March 1…